CELC – Celcuity Inc.
Celcuity Inc.CELC
$67.05Name : Celcuity Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,280,884,480.00
EPSttm : -4.72
Celcuity Inc.
$67.05
4.72%$3.32
CELC — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
25.35
Margin Of Safety %
Put/Call OI Ratio
0.59
EPS Next Q Diff
0.25
EPS Last/This Y
-1.1
EPS This/Next Y
4.89
Price
67.06
Target Price
150.85
Analyst Recom
1
Performance Q
-27.18
Upside
-345.9%
Beta
0.14
Ticker: CELC
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | CELC | 65.9 | 0.46 | 1.10 | 18044 |
| 2026-10-13 | CELC | 63.2 | 0.45 | 1.57 | 18027 |
| 2026-10-14 | CELC | 59.9 | 0.43 | 0.13 | 17925 |
| 2026-10-15 | CELC | 60.82 | 0.36 | 0.02 | 20175 |
| 2026-10-16 | CELC | 56.6 | 0.36 | 0.53 | 20369 |
| 2026-10-19 | CELC | 57.09 | 0.39 | 0.09 | 19222 |
| 2026-10-20 | CELC | 60.36 | 0.38 | 2.62 | 19659 |
| 2026-10-21 | CELC | 61.62 | 0.38 | 0.04 | 19893 |
| 2026-10-22 | CELC | 65.61 | 0.38 | 0.06 | 19973 |
| 2026-10-23 | CELC | 65.3 | 0.39 | 0.82 | 20177 |
| 2026-10-26 | CELC | 65.85 | 0.39 | 0.56 | 20259 |
| 2026-10-27 | CELC | 68.13 | 0.39 | 0.00 | 20410 |
| 2026-10-28 | CELC | 69.46 | 0.39 | 0.18 | 20488 |
| 2026-10-29 | CELC | 69.32 | 0.39 | 0.52 | 20650 |
| 2026-10-30 | CELC | 69.17 | 0.39 | 0.11 | 20642 |
| 2026-11-02 | CELC | 67.09 | 0.38 | 0.15 | 20974 |
| 2026-11-03 | CELC | 69.74 | 0.39 | 0.10 | 20903 |
| 2026-11-04 | CELC | 69.28 | 0.39 | 0.86 | 21047 |
| 2026-11-05 | CELC | 63.95 | 0.39 | 0.36 | 21095 |
| 2026-11-06 | CELC | 66.76 | 0.39 | 30.01 | 21148 |
| 2026-11-09 | CELC | 70.12 | 0.59 | 1.04 | 24084 |
| 2026-11-10 | CELC | 67.01 | 0.59 | 0.02 | 24243 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | CELC | 65.92 | -93.6 | - | -4.39 |
| 2026-10-13 | CELC | 63.23 | -93.6 | - | -4.39 |
| 2026-10-14 | CELC | 59.92 | -93.6 | - | -4.39 |
| 2026-10-15 | CELC | 60.38 | -93.6 | - | -4.39 |
| 2026-10-16 | CELC | 56.58 | -93.6 | - | -4.39 |
| 2026-10-19 | CELC | 57.08 | -93.6 | - | -4.39 |
| 2026-10-20 | CELC | 57.08 | -93.6 | - | -4.39 |
| 2026-10-21 | CELC | 60.06 | -93.6 | - | -4.39 |
| 2026-10-22 | CELC | 65.65 | -93.6 | - | -4.39 |
| 2026-10-23 | CELC | 65.29 | -93.6 | - | -4.39 |
| 2026-10-26 | CELC | 65.82 | -93.6 | - | -4.39 |
| 2026-10-27 | CELC | 68.11 | -93.6 | - | -4.39 |
| 2026-10-28 | CELC | 69.44 | -93.6 | - | -4.39 |
| 2026-10-29 | CELC | 69.33 | -93.6 | - | -4.39 |
| 2026-10-30 | CELC | 69.12 | -93.6 | - | -4.39 |
| 2026-11-02 | CELC | 67.11 | -93.6 | - | -4.39 |
| 2026-11-03 | CELC | 69.72 | -93.6 | - | -4.39 |
| 2026-11-04 | CELC | 69.33 | -93.6 | - | -4.39 |
| 2026-11-05 | CELC | 63.90 | -93.6 | - | -4.52 |
| 2026-11-06 | CELC | 66.77 | -96.8 | - | -4.52 |
| 2026-11-09 | CELC | 70.35 | -26.7 | - | -4.52 |
| 2026-11-10 | CELC | 67.06 | -61.6 | - | -4.32 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | CELC | -26.61 | 22.63 | 27.25 |
| 2026-10-13 | CELC | -26.61 | 22.63 | 27.25 |
| 2026-10-14 | CELC | -26.61 | 22.63 | 27.25 |
| 2026-10-15 | CELC | -26.61 | 22.63 | 27.25 |
| 2026-10-16 | CELC | -26.61 | 22.63 | 27.25 |
| 2026-10-19 | CELC | -26.62 | 22.78 | 27.25 |
| 2026-10-20 | CELC | -26.62 | 22.78 | 27.25 |
| 2026-10-21 | CELC | -26.61 | 22.78 | 27.25 |
| 2026-10-22 | CELC | -26.61 | 22.78 | 27.25 |
| 2026-10-23 | CELC | -26.61 | 22.78 | 27.25 |
| 2026-10-26 | CELC | -26.62 | 25.24 | 27.25 |
| 2026-10-27 | CELC | -26.61 | 25.24 | 25.45 |
| 2026-10-28 | CELC | -26.61 | 25.24 | 25.45 |
| 2026-10-29 | CELC | -26.61 | 25.24 | 25.45 |
| 2026-10-30 | CELC | -26.61 | 25.24 | 25.45 |
| 2026-11-02 | CELC | -26.61 | 25.17 | 25.45 |
| 2026-11-03 | CELC | -26.61 | 25.17 | 25.45 |
| 2026-11-05 | CELC | -26.61 | 25.17 | 25.45 |
| 2026-11-06 | CELC | -26.61 | 25.17 | 25.45 |
| 2026-11-09 | CELC | -26.33 | 25.02 | 25.35 |
| 2026-11-10 | CELC | -26.33 | 25.02 | 25.35 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.33
Avg. EPS Est. Current Quarter
-1.18
Avg. EPS Est. Next Quarter
-1.08
Insider Transactions
-26.33
Institutional Transactions
25.02
Beta
0.14
Average Sales Estimate Current Quarter
11
Average Sales Estimate Next Quarter
35
Fair Value
Quality Score
6
Growth Score
22
Sentiment Score
58
Actual DrawDown %
55.6
Max Drawdown 5-Year %
-70.8
Target Price
150.85
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
-4.71
Average EPS Est. Cur. Y
-4.32
EPS Next Y. (Est.)
0.57
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
Relative Volume
0.63
Return on Equity vs Sector %
319.5
Return on Equity vs Industry %
339.2
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.07
EBIT Estimation
◆
CELC
Healthcare
$67.05
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
47.1
Range 1M
68.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-36.3%
EPS NY
47.1%
52W%
13.8%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-14.4% upside
Upside
-14.4%
Quality
6
CELC — P/E HistoricalDiagnostics & Research
Celcuity Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 155
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
CELC
Latest News
—
Caricamento notizie per CELC…
stock quote shares CELC – Celcuity Inc. Stock Price stock today
news today CELC – Celcuity Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CELC – Celcuity Inc. yahoo finance google finance
stock history CELC – Celcuity Inc. invest stock market
stock prices CELC premarket after hours
ticker CELC fair value insiders trading